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861-3 A Phase I Open-Label Dose Escalation Trial of a 
Monoclonal Antibody Against Tissue Factor (Sunol 
cH36) in Stable Coronary Artery Disease: Results of the 
PROXIMATE-TIMI 27 Trial
David A. Morrow, Rafael F. Sequeira, Tim D. Henry, Lawrence A. Galitz, Howard A. 
Cooper, Benjamin M. Scirica, Graham C. Wong, Hing C. Wong, Carolyn H. McCabe, 
Elliott M. Antman, Brigham & Women's Hospital, Boston, MA
Tissue factor (TF) is a critical participant in the genesis of acute coronary syndromes.
Sunol cH36 is a chimeric monoclonal antibody to TF that blocks binding of factor X to
TF:VIIa. This novel anticoagulant had not yet been tested in humans. METHODS: We
assessed the safety & pharmacokinetics of cH36 in pts with stable CAD receiving aspirin.
The safety analysis included all adverse events (AEs) with a focus on bleeding during 7
weeks post-dose. RESULTS: Five doses of cH36 were given IV x1 among 26 subjects
(3-8 per dose tier). Preliminary results show no major bleeding (>2 g/dL fall in Hgb).
Spontaneous minor bleeding exhibited a dose-related pattern (Table). Notably, most
bleeding events were clinically consistent with platelet-mediated bleeding (eg. gum/
tongue). Through expected interaction with a human tissue-factor based assay, cH36
exhibited a dose-related prolongation of the prothrombin time. There were no other lab
abnormalities or rx-related AEs. Human anti-chimeric antibody was not elevated at 7
wks. PK data will also be presented with the final study results. CONCLUSION: In this
initial experience in humans, cH36 exhibited dose-related anticoagulant effects manifest
with minor bleeding. These data support additional study at doses <0.1 mg/kg. We postu-
late that the platelet-mediated bleeding observed with this potent inhibitor of thrombin
generation reflects important networking between thrombin & platelet pathways that may
prove clinically relevant with this novel class of anticoagulants.
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861-4 Medullar Neurostimulation Is a Safe Alternative for 
Refractory Angina
Maria M. Irurita, Carlos Culebras, Presentacion Vila, Juncal Irurita, Candida Deniz, Jose 
Fuentes, Maria Teresa Martinez de Saavedra, Isabel Molina, Florentino Sanchez, 
Ricardo Chirino, Vicente Nieto, Insular Hospital, Las Palmas de Gran Canaria, Spain, 
Las Palmas GC University, Las Palmas GC, Spain
Refractory angina defined as severe angina, resistant to maximum medical therapy and
unsuitable for further revascularization. Medullar neurostimulation (MNS), with proved
beneficial effects in a series of chronic painful conditions, could theoretically become a
safe and effective therapeutic alternative.
To assess whether patients with refractory angina (RA), improve their quality of life with-
out increasing morbi-mortality, 34 patients meeting criteria for RA were studied after a
minor surgical procedure to implant a medullar neurostimulator. Consistent with inclusion
criteria, all patients had persistent ischemia, 56% were males, with a mean age of 70 +6
y-o, 97% had hypertension, 81% dyslipidemia, 78% diabetes, 70% peripheral arteriopa-
thy, and 28% chronic renal failure. CHD had lasted 9 +5 years on average, 94% had three
vessels disease and 72% had been previously revascularized. Objective and subjective
clinical and functional variables, including a quality of life scale (Euroquol test) were
assessed at baseline (B) and after 36 months of follow-up (F). Following neurostimulation
both functional classes improved NYHA (3.2 +0.8 B vs. 1.9 +0.8 F; p<0.001) and Cana-
dian (3.5 +0.5 B to 1.7 +0.8 F; p<0.001), angina dropped from 10 to 7 episodes/week
(p<0.001), ejection fraction raised from 36.7 +8.9 to 43.7 +2.5 (p<0.03), and exercise
time increased from 2.2 +1.6 to 4.2 +1.8 minutes (p<0.01). Health brief on mobility (2.19
+0.3 B vs 1.44 +0.5 F), personal care (2.03 +0.6 B vs. 1.11 +0.4 F), daily activity (3.3
+0.5 B vs. 1.4 +0.4 F), chest pain (2.9 +0.2 B vs. 1.3 +0.4 F) and depression/anxiety
parameters (2.7 +0.5 B vs 1.6 +0.5 F), improved by 81% (p<0.001). No differences were
found in body mass index or isotopic perfusion studies when available for comparison (6
patients). Up to 88% has survived 36 months, and for the time being only 5 p have been
hospitalized for cardiac causes (15.6%; p<0.005).
In conclusion, our study shows that in refractory angina, medullar neurostimulation
grants mid-term improvement in quality of life, clinical, and functional parameters. Med-
ullar neurostimulation is an alternative therapy with a small impact on morbility and mor-
tality in selected high risk symptomatic patients.
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869-1 Relationship Between Time to Reperfusion, ST-Segment 
Resolution, Myocardial Blush Scores and Mortality With 
Primary Percutaneous Coronary Intervention for Acute 
Myocardial Infarction: Results From the CADILLAC Trial
Bruce R. Brodie, Costantino Costantini, Eve Aymong, Thomas D. Stuckey, David A. Cox, 
Peter Zimetbaum, Michael McLaughlin, Eulogio Garcia, Mark A. Turco, Roxana Mehran, 
Cindy L. Grines, Alexandra J. Lansky, Gregg W. Stone, LeBauer Cardiovascular 
Research Foundation and Moses Cone Heart and Vascular Center, Greensboro, NC, 
Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New 
York, NY
Background: Achieving optimum microvascular reperfusion is important for optimizing
outcomes with primary PCI . The relationship between time to reperfusion and measures
of microvascular reperfusion with primary PCI has not been studied.
Methods: The CADILLAC Trial randomized 2,082 pts with AMI to PTCA vs stenting +/-
abciximab. Analyses of myocardial blush (MB) from post-PCI cineangiograms (n=1256)
and ST-segment resolution (STR) from pre and post-PCI ECGs (n=700) were performed
at core laboratories.
Results: Early time to reperfusion (<3 vs 3-6 vs >6 hrs) was associated with a higher fre-
quency of Grade 2-3 MB (55% vs 53% vs 44%, p=0.007) and a higher frequency of com-
plete (>70%) STR (64% vs 68% vs 47%, p=0.0002). Complete STR (>70% vs <70%)
was associated with a higher frequency of Grade 2-3 MB (56% vs 40%, p=0.0007),
although 40% of pts with poor STR had good blush scores and 44% of pts with complete
STR had poor blush scores. One year mortality was lowest with optimum microvascular
reperfusion (complete STR and Grade 2-3 MB) and highest with poor microvascular rep-
erfusion (poor STR and Grade 0-1 MB) (0.6% vs 9.9%, p=0.006). Mortality was excellent
with optimal microvascular reperfusion regardless of time to reperfusion (<3 vs >3 hrs)
(0% vs 1.0%, p=NS), but time to reperfusion did impact mortality in patients with poor
microvascular reperfusion (5.9% vs 11.9%, p=0.54). 
Conclusion: Early time to reperfusion is associated with a greater likelihood of success-
ful microvascular reperfusion after primary PCI. Delayed time to reperfusion negatively
impacts mortality only in patients in whom successful microvascular reperfusion cannot
be restored. While STR and MB are highly correlated, the sizable number of pts with dis-
cordant data suggest that these 2 methods measure different aspects of microvascular
reperfusion. Optimum survival benefit requires achievement of both complete STR and
Grade 2-3 MB.
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869-2 Impact of Intravenous Beta-Blockade During Primary 
Percutaneous Intervention on Convalescent Left 
Ventricular Function
Amir Halkin, Cindy L. Grines, David A. Cox, Eulogio Garcia, Roxana Mehran, James E. 
Tcheng, John J. Griffin, Giulio Guagliumi, Bruce Brodie, Mark Turco, Barry D. Rutherford, 
Eve A. Aymong, Alexandra J. Lansky, Gregg W. Stone, The Cardiovascular Research 
Foundation, New York, NY
Background: We have shown that intravenous (IV) beta-blockers (BB) administration dur-
ing primary percutaneous intervention (PCI) imparts a survival benefit, an effect limited to
patients not on chronic oral β-blockade. Whether periprocedural IV BB also improve myo-
cardial recovery is unknown. Methods and Results: In the CADILLAC trial, 2,082 patients
with AMI were randomized to either stenting or angioplasty, +abciximab. IV BB were used
in 1,136 patients (54.5%, BB+), and not in the remaining 946 patients (45.5%, BB-).
Paired left ventriculograms were available at baseline and at 7-month follow-up in 230
and 233 BB+ and BB- patients, respectively.
Baseline LVEF was lower in BB+ patients, though follow-up LVEF was similar in both
groups corresponding to a significantly greater incremental improvement in LVEF in the
BB+ group (Figure). The increase in LVEF from baseline to follow-up in BB+ group was
most pronounced in patients not taking oral BB prior to admission. In patients maintained
on BB prior to admission, the change in LVEF was similar in BB+ and BB- patients.
By multivariate analysis, IV BB in patients not receiving oral BB prior to admission was an
independent predictor of greater increase in LVEF from baseline to 7-month follow-up (β
coefficient=3.24, p<0.0001).
Conclusions. In patients undergoing catheter-based reperfusion for myocardial infarction,
Dose Sunol cH36 (mg/kg)
0.03 0.06 0.08 0.10 0.30
Enrolled (N) 8 4 4 7 3
Major Bleeding (subjects) 0 0 0 0 0
Spont. Minor Bleeding (subjects) 0 1 1 4 3
  Gum/tongue bleeding 0 0 1 2 3
